View Item 

Show simple item record

A Placebo‐Controlled Double‐Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate Cancer
dc.contributor.authorvan Die, M. Diana
dc.contributor.authorWilliams, Scott G.
dc.contributor.authorEmery, Jon
dc.contributor.authorBone, Kerry M.
dc.contributor.authorTaylor, Jeremy M.G.
dc.contributor.authorLusk, Elizabeth
dc.contributor.authorPirotta, Marie V.
dc.date.accessioned2017-04-14T15:11:45Z
dc.date.available2018-07-09T17:42:24Zen
dc.date.issued2017-05
dc.identifier.citationvan Die, M. Diana; Williams, Scott G.; Emery, Jon; Bone, Kerry M.; Taylor, Jeremy M.G.; Lusk, Elizabeth; Pirotta, Marie V. (2017). "A Placebo‐Controlled Double‐Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate Cancer." The Prostate 77(7): 765-775.
dc.identifier.issn0270-4137
dc.identifier.issn1097-0045
dc.identifier.urihttps://hdl.handle.net/2027.42/136500
dc.publisherElsevier Churchill Livingstone
dc.publisherWiley Periodicals, Inc.
dc.subject.otherherbal medicine
dc.subject.otherphytotherapy
dc.subject.otherbotanical medicine
dc.subject.otherrandomized controlled trial
dc.subject.otherearly prostate cancer
dc.titleA Placebo‐Controlled Double‐Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate Cancer
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136500/1/pros23317_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136500/2/pros23317.pdf
dc.identifier.doi10.1002/pros.23317
dc.identifier.sourceThe Prostate
dc.identifier.citedreferenceBettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high‐grade prostate intraepithelial neoplasia: A preliminary report from a one‐year proof‐of‐principle study. Cancer Res 2006; 66 ( 2 ): 1234 – 1240.
dc.identifier.citedreferenceVerhoeven DT, Goldbohm RA, van Poppel G, Verhagen H, van den Brandt PA. Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol Biomarkers Prev 1996; 5 ( 9 ): 733 – 748.
dc.identifier.citedreferenceBishayee A. Cancer prevention and treatment with resveratrol: From rodent studies to clinical trials. Cancer Prev Res (Phila) 2009; 2 ( 5 ): 409 – 418.
dc.identifier.citedreferenceBrooks JD, Paton VG, Vidanes G. Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer Epidemiol Biomarkers Prev 2001; 10 ( 9 ): 949 – 954.
dc.identifier.citedreferenceChoi S, Lew KL, Xiao H, Herman‐Antosiewicz A, Xiao D, Brown CK, Singh SV. D,L‐Sulforaphane‐induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf‐1. Carcinogenesis 2007; 28 ( 1 ): 151 – 162.
dc.identifier.citedreferenceDorai T, Cao YC, Dorai B, Buttyan R, Katz AE. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 2001; 47 ( 4 ): 293 – 303.
dc.identifier.citedreferenceHerman‐Antosiewicz A, Xiao H, Lew KL, Singh SV. Induction of p21 protein protects against sulforaphane‐induced mitotic arrest in LNCaP human prostate cancer cell line. Mol Cancer Ther 2007; 6 ( 5 ): 1673 – 1681.
dc.identifier.citedreferenceKeum YS, Khor TO, Lin W, Shen G, Kwon KH, Barve A, Li W, Kong AN. Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: Implication of induction of Nrf2, HO‐1, and apoptosis and the suppression of Akt‐dependent kinase pathway. Pharm Res 2009; 26 ( 10 ): 2324 – 2331.
dc.identifier.citedreferenceKhan N, Adhami VM, Mukhtar H. Review: Green tea polyphenols in chemoprevention of prostate cancer: Preclinical and clinical studies. Nutr Cancer 2009; 61 ( 6 ): 836 – 841.
dc.identifier.citedreferenceMyzak MC, Hardin K, Wang R, Dashwood RH, Ho E. Sulforaphane inhibits histone deacetylase activity in BPH‐1, LnCaP, and PC‐3 prostate epithelial cells. Carcinogenesis 2006; 27 ( 4 ): 811 – 819.
dc.identifier.citedreferencePandey M, Gupta S. Green tea and prostate cancer: From bench to clinic. Front Biosci (Elite Ed) 2009; 1: 13 – 25.
dc.identifier.citedreferenceShehzad A, Lee J, Lee YS. Curcumin in various cancers. Biofactors 2013; 39 ( 1 ): 56 – 68.
dc.identifier.citedreferenceSmoliga JM, Baur JA, Hausenblas HA. Resveratrol and health‐a comprehensive review of human clinical trials. Mol Nutr Food Res 2011; 55 ( 8 ): 1129 – 1141.
dc.identifier.citedreferenceStrimpakos AS, Sharma RA. Curcumin: Preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008; 10 ( 3 ): 511 – 545.
dc.identifier.citedreferenceBrausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: Two years later. A follow‐up update. Eur Urol 2008; 54 ( 2 ): 472 – 473.
dc.identifier.citedreferenceChoan E, Segal R, Jonker D, Malone S, Reaume N, Eapen L, Gallant V. A prospective clinical trial of green tea for hormone refractory prostate cancer: An evaluation of the complementary/alternative therapy approach. Urol Oncol 2005; 23 ( 2 ): 108 – 113.
dc.identifier.citedreferenceJatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CYF, Flynn PJ. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003; 97 ( 6 ): 1442 – 1446.
dc.identifier.citedreferenceMcLarty J, Bigelow RLH, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate‐specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res 2009; 2 ( 7 ): 673 – 682.
dc.identifier.citedreferenceCipolla BG, Mandron E, Lefort JM, Coadou Y, Della Negra E, Corbel L, Le Scodan R, Azzouzi AR, Mottet N. Effect of sulforaphane in men with biochemical recurrence after radical prostatectomy. Cancer Prev Res (Phila) 2015; 8 ( 8 ): 712 – 719.
dc.identifier.citedreferenceThomas R, Williams M, Sharma H, Chaudry A, Bellamy P. A double‐blind, placebo‐controlled randomised trial evaluating the effect of a polyphenol‐rich whole food supplement on PSA progression in men with prostate cancer‐the UK NCRN Pomi‐T study. Prostate Cancer Prostatic Dis 2014; 17 ( 2 ): 180 – 186.
dc.identifier.citedreferencevan Die MD, Bone KM, Emery J, Williams SG, Pirotta MV, Paller CJ. Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: A systematic review of randomised trials. BJU Int 2016; 117 ( Suppl 4 ): 17 – 34.
dc.identifier.citedreferenceBoffetta P, Thies F, Kris‐Etherton P. Epidemiological studies of oats consumption and risk of cancer and overall mortality. Br J Nutr 2014; 112 ( Suppl 2 ): S14 – S18.
dc.identifier.citedreferenceEgeberg R, Olsen A, Christensen J, Johnsen NF, Loft S, Overvad K, Tjonneland A. Intake of whole‐grain products and risk of prostate cancer among men in the danish diet, cancer, and health cohort study. Cancer Causes Control 2011; 22 ( 8 ): 1133 – 1139.
dc.identifier.citedreferenceLink RE, Shariat SF, Nguyen CV, Farr A, Weinberg AD, Morton RA, Richardson B, Bernard D, Slawin KM. Variation in prostate specific antigen results from two different assay platforms: Clinical impact on 2304 patients undergoing prostate cancer screening. J Urol 2004; 171 ( 6 Pt 1 ): 2234 – 2238.
dc.identifier.citedreferenceBone K, Mills S. Principles and practice of phytotherapy, 2nd ed. Edinburgh, London, New York: Elsevier Churchill Livingstone; 2013.
dc.identifier.citedreferencePaller CJ, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis 2014; 17 ( 1 ): 28 – 33.
dc.identifier.citedreferenceUchio EM, Aslan M, Wells CK, Calderone J, Concato J. Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med 2010; 170 ( 15 ): 1390 – 1395.
dc.identifier.citedreferenceKlotz LH. PSA recurrence: Definitions, PSA kinetics, and identifying patients at risk. Can J Urol 2006; 13 ( Suppl 2 ): 43 – 47.
dc.identifier.citedreferenceAntonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, Eisenberger MA. Changes in PSA kinetics predict metastasis—free survival in men with PSA‐recurrent prostate cancer treated with nonhormonal agents: Combined analysis of 4 phase II trials. Cancer 2012; 118 ( 6 ): 1533 – 1542.
dc.identifier.citedreferenceAntonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA. The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: Long‐term follow‐up. BJU Int 2012; 109 ( 1 ): 32 – 39.
dc.identifier.citedreferencePaller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, Stockton BR, Hertzman BL, Efros MD, Roper RP, Liker HR, Carducci MA. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis 2012; 16 ( 1 ): 50 – 55.
dc.identifier.citedreferencePaller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: Evolving standards of care and new directions. Clin Adv Hematol Oncol 2013; 11 ( 1 ): 14 – 23.
dc.identifier.citedreferenceAmes SC, Tan WW, Ames GE, Stone RL, Rizzo TD, Jr., Heckman MG, Crook JE, Clark MM, Rummans TA, Werch CE. Quality of life of men with biochemical recurrence of prostate cancer. J Psychosoc Oncol 2008; 26 ( 2 ): 17 – 34.
dc.identifier.citedreferenceFreedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer‐specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294 ( 4 ): 433 – 439.
dc.identifier.citedreferenceBishop FL, Rea A, Lewith H, Chan YK, Saville J, Prescott P, Elm EV, Lewith GT. Complementary medicine use by men with prostate cancer: A systematic review of prevalence studies. Prostate Cancer Prostatic Dis 2010; 14 ( 1 ): 1 – 13.
dc.identifier.citedreferenceCohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 2000; 92 ( 1 ): 61 – 68.
dc.identifier.citedreferenceGraf BA, Milbury PE, Blumberg JB. Flavonols, flavones, flavanones, and human health: Epidemiological evidence. J Med Food 2005; 8 ( 3 ): 281 – 290.
dc.identifier.citedreferenceJain MG, Hislop GT, Howe GR, Ghadirian P. Plant foods, antioxidants, and prostate cancer risk: Findings from case‐control studies in Canada. Nutr Cancer 1999; 34 ( 2 ): 173 – 184.
dc.identifier.citedreferenceJeffery EH, Keck AS. Translating knowledge generated by epidemiological and in vitro studies into dietary cancer prevention. Mol Nutr Food Res 2008; 52 ( Suppl 1 ): S7 – 17.
dc.identifier.citedreferenceKirsh VA, Peters U, Mayne ST, Subar AF, Chatterjee N, Johnson CC, Hayes RB. Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst 2007; 99 ( 15 ): 1200 – 1209.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
pros23317_am.pdf
Size:
160.8KB
Format:
PDF
View/Open
Name:
pros23317.pdf
Size:
166.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.